venetoclax
Large Study Identifies Potential Therapeutic Targets for MDS Patients who Fail Initial Treatment
Premium
The study showed that the stem cell profiles of MDS patients could be used to stratify them into two subgroups associated with differential response to Venclexta.
Tibsovo, Azacitidine Combo Shows Improved Survival, Response in Newly Diagnosed IDH1-Mutant AML
Researchers at the ASH annual meeting suggested that Tibsovo-azacitidine could be a better option than Venclexta-azacitidine for chemo ineligible IDH1-mutant AML patients.
Researchers presented data exploring CLL patients' outcomes on fixed-duration combination regimens and on using uMRD to decide which patients can stop treatment.
UK's NICE Recommends Venclyxto, Gazyva for Chronic Lymphocytic Leukemia
The agency recommended the combination for previously untreated CLL patients with certain genetic mutations, including those with a 17p deletion or TP53 mutation.
Adaptive Biotechnologies, Genentech Partner on MRD Testing in Venetoclax Clinical Trial
Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.